Surgical interventions such as liposuction or glandular excision carry their own set of risks including infection, scarring, and anesthesia complications. Many individuals with gynecomastia experience feelings of self-consciousness, embarrassment, and low self-esteem due to their appearance. It is always recommended to consult a healthcare professional for an accurate diagnosis and personalized treatment plan. Balancing hormone levels through medications like SERMs or aromatase inhibitors can help reduce breast tissue growth. For men having low testosterone levels, TRT can help balance hormone levels and reduce breast tissue growth. A male breast cancer that involves chest fat rather than glandular tissue. For example, hormone-producing tumors, liver disease, or thyroid disorders can also cause gynecomastia through hormonal imbalances that lead to breast tissue growth. But if it persists into adulthood then surgeons recommend a treatment to reduce the risk of breast cancer in tissue. If estrogen levels are too high or androgen levels are too low, breast tissue may enlarge. In these patients, testosterone replacement may worsen the gynecomastia because of the aromatization of T to E2. The major medical intervention options are androgens, anti-estrogens and aromatase inhibitors. Although no medical treatments cause the complete regression of gynecomastia, they may provide partial regression, or symptomatic relief. In some cases, treatment may be needed, for example if severe breast enlargement, pain, or tenderness interferes with the patient's normal daily activities. If medical intervention is planned, it should therefore be used in the early stages of gynecomastia.2,5 Below, the treatment options are discussed in more detail. A family history of breast cancer increases the risk of breast cancer in males. Men with Klinefelter’s syndrome, who have testicular failure shortly after puberty, have a 58-fold higher risk than normal males for breast cancer, with an absolute risk that approaches 3%.11 Breast cancer has been reported in male to female transsexuals who were castrated and given high dose oestrogen. We searched Medline for English language papers with the key words "gynaecomastia", "gynecomastia", and "male breast cancer"; the Cochrane database for clinical trials; our personal archives of references; and websites with those terms. But if it’s caused by long-term hormonal imbalances or other medical conditions then treatment is needed to reduce or get rid of the breast tissue. In some cases, the cause of gynecomastia remains unclear even after thorough evaluations, and these cases are classified as idiopathic gynecomastia. We will also dive into statistics, causes, risk factors, and long-term outcomes. It is a common condition that affects a significant number of men worldwide. Gynecomastia that occurs because of hormonal fluctuations with growth or aging cannot be prevented. Management is extrapolated from female breast cancer and from case series in single institutions. No prospective studies have been done of male breast cancer. Goals of surgery include removing abnormal breast tissue, restoring the normal male breast contour, and reducing pain. Almost no lobular tissue exists in normal adult male breast tissue. It is important to note that results are cosmetically unsatisfactory in 50% of patients. The effective dose of raloxifen (Rlx, an alternative anti-estrogen) was found to be 60 mg/day. Studies revealed that the effective dose range of Tmx in gynecomastia is 10-20mg/day for 2-4m. Although both Tmx and danazole have been used to treat gynecomastia, the effect of 20-mg/day Tmx gave 78% resolution, which was better 400-mg/day danazol, which had only a 40% resolution rate. In a randomized, double blind study, danazole significantly reduced breast tenderness and size. The first reported controlled trial investigating the efficacy of danazole in adult idiopathic gynecomastia was published in 1979 and showed that 200mg/day danazole could effectively control the symptoms, although no effect was found in cases of pubertal gynecomastia. The surgical technique used depends on the degree of the gynecomastia and the distribution and proportion of the different breast components (fat, parenchyma and looseness of the skin envelope). Testolactone is an aromatase inhibitor was tested in a small, uncontrolled trial of pubertal gynecomastia; results were positive.7,11 Overall, the use of aromatase inhibitors is supported by incomplete evidence and the potential benefits and adverse effects should be considered before commencing treatment. Aromatase Inhibitors–these powerful agents block estrogen synthesis and as such decrease the estrogen to androgen ratio. Because it rapidly reduces pain, it should be considered a first-line treatment for symptomatic cases of acute gynecomastia, or those that fail to resolve spontaneously. Gynecomastia (enlarged male breast tissue) most often happens due to an imbalance of testosterone and estrogen. Gynecomastia, a condition characterized by the enlargement of breast tissue in males, can be a source of physical and emotional discomfort. Hormones such as estrogen and testosterone play a significant role in maintaining the balance of breast tissue in both males and females. Gynecomastia, a condition characterized by the enlargement of breast tissue in males, is a topic that deserves understanding and attention. Such evaluation is unnecessary for boys at puberty, for typical asymptomatic senile changes, for enlargement consisting mostly of adipose tissue, for men taking drugs known to cause gynaecomastia, or for physical findings strongly suggesting breast cancer. Table 2 shows other genetic markers considered possible risk factors for male breast cancer. Pubertal gynecomastia usually begins at age years-old and peaks at ages 13-14. This wide variation is likely due to differences in what is considered to be normal sub-areolar glandular tissue, the diagnosing physician and most importantly variations in the age distribution of the patient populations. Normally, this condition regresses within 2-3 weeks of delivery.2,5,8,11 The second peak occurs during puberty and has a prevalence of 4-69%. However, in more severe cases, medical and/or surgical intervention is required.
